High-dose Wegovy leads to substantial weight loss in trial

High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound
A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.
Kailera reports Zepbound-rivaling weight loss in phase 2 obesity trial
Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes can muscle in on the market. Kailera and partner Jiangsu Hengrui Pharmaceuticals linked the injectable GLP-1/GIP receptor dual agonist to 22.8% mean weight loss after 36 weeks.
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,
Wegovy at Higher Dose Achieves Greater Weight Loss in Trial
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side effects.
Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial
Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy led to 20.7% weight loss over 72 weeks compared to 17.5% weight loss achieved by regular semaglutide in a late-stage trial.
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
People25d
Zepbound Weight Loss Medication Approved by FDA to Treat Sleep Apnea
Shelby Knowles/Bloomberg via Getty The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug ...
News Nation on MSN19d
Weight loss drug Zepbound approved to help sleep apnea patients
( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...
Yahoo29d
The popular weight-loss drug Zepbound can now be used to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication ...
Lilly Shares on Track for Worst Day Since 2021 After Downbeat Zepbound Sales Forecast
The company's shares were trading at $740.80, on track for their worst single-day decline in nearly four years. Lilly's stock ...
UPI28d
FDA approves weight-loss drug Zepbound to treat sleep apnea
Dec. 21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
USA Today1mon
FDA: Weight loss drug Zepbound, diabetes drug Mounjaro no longer in shortage
On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...